I am a Postdoctoral Researcher in Drug Discovery Technologies Group at IBM Thomas J. Watson Research Center. Before IBM, I was a Scientist, Computational Biology at NuMedii, Inc. I also did research at National Center for Toxicological Research (NCTR), Food and Drug Administration (FDA).
My research interest include bioinformatics, machine learning, statistical analysis and their applications in drug safety evaluation, drug repositioning and precision medicine. I leverage the information of knowledgebases, in silico chemical-protein interactome (CPI), gene expression data and post-market survilience data. In the past, I have:
1. Combined machine learning, similarity analytics and structural modeling to predict drug repositioning for a pharmaceutical client;
2. Combined machine learning and structural modeling for drug safety evaluation; and
3. Participated in developing (a) a deep learning method for drug safety evaluation and risky structural identification, (b) pathway analytics for adverse drug reaction prediction and (c) active learning for drug candidate prioritization.
Recently, I leverage deep learning technologies to improve structural modeling, binding prediction, drug design and property prediction.